Glycosylation can be a critical quality attribute in biologic manufacturing. In particular, it has
implications on the half‐life, immunogenicity, and pharmacokinetics of therapeutic …

Monoclonal antibody (mAb)-based therapies have been a major advance in oncology
patient care, even though they represent a significant healthcare cost. Biosimilars, launched …

Abstract Background and Objective Immune checkpoint inhibitors (ICIs) have become a
cornerstone in cancer treatment. With high treatment costs and an increasing number of …

Abstract Summary This 78-week (18-month) study conducted in 479 postmenopausal
women with osteoporosis evaluated the efficacy, pharmacodynamics, pharmacokinetics …

Biologicals have become an integral part of cancer treatment both as therapeutic agents and
as supportive care agents. It is important to know that biologics are large, complex molecular …

Antibody-drug conjugates (ADCs) are biotherapeutics consisting of a tumor-targeting
monoclonal antibody (mAb) linked covalently to a cytotoxic drug. Early generation ADCs …

Pertuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer
in combination with trastuzumab. Charge variants of trastuzumab have been extensively …

Purpose Bevacizumab is a recombinant humanized monoclonal antibody that inhibits
vascular endothelial growth factor-specific angiogenesis in some cancers. MYL-1402O is a …

Purpose To assess efficacy and safety of trastuzumab biosimilars in comparison to the
reference drug through a systematic review and meta-analysis of randomized controlled …

Current approved antiviral therapies for chronic hepatitis B virus (HBV) infection are limited
to either nucleotide or nucleoside analogues or pegylated interferon α, all of which can …